Sensorion, a pioneering clinical-stage biotechnology company specializing in the development of novel therapies for hearing loss disorders, is excited to announce its participation in the upcoming 27th Annual American Society of Cell and Gene Therapy (ASGCT) Meeting. The event, which will take place from May 7-11, 2024, in Baltimore, United States, brings together leading experts in the field of cell and gene therapy.
As a company at the forefront of innovative treatments for hearing loss, Sensorion’s presence at the ASGCT Annual Meeting underscores its commitment to advancing groundbreaking research and collaborating with industry leaders. The company’s participation in this prestigious event highlights its dedication to restoring, treating, and preventing various hearing loss disorders through cutting-edge biotechnology solutions.
